ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0921

Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling

Hannah Johnson1, Wenxian Zhou2, Michael Duryee1, Carlos Hunter1, Geoffrey Thiele1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Bellevue, NE

Meeting: ACR Convergence 2025

Keywords: autoantigens, Cell-signalling molecules, Inflammation, innate immunity, macrophages

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0916–0933) Innate Immunity Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Citrulline (CIT) and malondialdehyde-acetaldehyde (MAA) co-adduct native proteins in RA tissues to create a dual pro-inflammatory and pro-fibrotic milieu. Our previous work demonstrated that supernatants from macrophages stimulated with CIT-MAA co-modified fibrinogen induce inflammatory, fibrotic, and invasive phenotypes in synovial and lung fibroblasts. However, the intracellular signaling pathways preceding cytokine release remain poorly defined. The aim of this study was to elucidate the inflammatory signaling pathways in macrophages following stimulation with CIT-MAA co-modified fibrinogen.

Methods: The human monocytic cell line (U-937) was differentiated into macrophages (M0 cells) using phorbol 12-myristate-13-acetate (PMA) and then stimulated with fibrinogen (FIB) that was unmodified, MAA-modified (FIB-MAA), CIT-modified (FIB-CIT), or CIT-MAA co-modified (FIB-CIT-MAA). After 1-hr of antigen stimulation, cells were lysed and protein was analyzed using Western blot analysis targeting the phosphorylated forms and total levels of p38 MAPK, NF-κB (p65), ERK1/2, STAT1, STAT3, STAT6, Akt1, Akt2, JNK, and β-actin. After 48-hrs of stimulation, supernatants were collected and analyzed by ELISA for concentrations of TNFα, IL-1β, IL-6, and MCP-1. After initial testing by Western blot, for each treatment group, there was a replicate group pre-treated with a p38 inhibitor (BIRB-796) or an NF-κB inhibitor (BAY 11-7085) for 1-hr before antigen stimulation. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparisons test.

Results: Western blot demonstrated that M0 cells treated with FIB-CIT had significantly increased p38 and NF-κB phosphorylation compared to unmodified FIB, with FIB-CIT-MAA further enhancing phosphorylation of these specific signaling molecules (Fig 1). No significant changes were observed in ERK1/2 and STAT1 following stimulation with any of the antigens. Additionally, phosphorylated Akt1, Akt2, JNK, STAT3, and STAT6 were not detected. Inhibition of signaling pathways after pre-treatment with p38 MAPK and NF-κB inhibitors was validated by Western blot. ELISA revealed that FIB-CIT-MAA stimulation significantly increased secretion of TNF-α, IL-1β, IL-6, and MCP-1 compared to both unmodified FIB, FIB-MAA, and FIB-CIT. Addition of inhibitors to p38 and/or NF-κB decreased release of all 4 cytokines, but only NF-κB inhibition fully abrogated their release (Fig 2).

Conclusion: CIT-MAA co-modified fibrinogen stimulates macrophage activation via the p38 and NF-κB pathways, promoting secretion of pro-inflammatory mediators including TNF-α, IL-1β, IL-6, and MCP-1. Inhibition of these pathways attenuates inflammatory cytokine production, supporting a mechanistic link between CIT-MAA adducts and disease progression in RA. Future research will validate this finding using human monocytes and identify whether agents targeting these post-translational modifications as well as downstream signaling pathways have the potential to attenuate RA progression.

Supporting image 1Figure 1. Intracellular Signaling Pathways Activated after Macrophage Stimulation Demonstrated by Western Blot. Macrophages were stimulated for 1-hr with fibrinogen (FIB) that was unmodified or modified with citrulline (CIT) and/or malondialdehyde-acetaldehyde (MAA) prior to measurement of intracellular signaling. Band intensity was quantified using KwikQuant Image Analyzer software. Graphs are plotted as a phosphorylated protein normalized to total protein. Note: phosphorylated Akt1, Akt2, JNK, STAT3, and STAT6 not detected (not shown); One-way ANOVA was performed and the statistical differences between groups are shown in *: * p < 0.05; ** p < 0.01; *** p < 0.001.

Supporting image 2Figure 2. ELISA Demonstrating Decreased Cytokine Production in Macrophages After Inhibition of p38 or NF-κB. 48-hr cytokine concentrations in supernatants were measured for; A) TNFα, B) IL-6, C) IL-1β, and D) MCP-1. One-way ANOVA was performed and the statistical differences between groups are shown in *: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.


Disclosures: H. Johnson: None; W. Zhou: None; M. Duryee: None; C. Hunter: None; G. Thiele: None; T. Mikuls: Amgen, 2, 5, Merck/MSD, 1, Olatech Therapeutics, 1, UCB, 1.

To cite this abstract in AMA style:

Johnson H, Zhou W, Duryee M, Hunter C, Thiele G, Mikuls T. Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/fibrinogen-co-modified-with-malondialdehyde-acetaldehyde-and-citrulline-promotes-pro-inflammatory-macrophage-differentiation-through-p38-and-nf-%ce%bab-signaling/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fibrinogen-co-modified-with-malondialdehyde-acetaldehyde-and-citrulline-promotes-pro-inflammatory-macrophage-differentiation-through-p38-and-nf-%ce%bab-signaling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology